Ultragenyx Setrusumab Phase 3 Miss Narrows Pipeline Focus

Ultragenyx Pharmaceutical (RARE) shares fell after the company's Phase 3 trial for setrusumab failed to reduce fracture rates in patients with osteogenesis imperfecta, the brittle bone disease. The drug did not hit the primary endpoint, the company said.

Setrusumab had been one of two late-stage programs carrying the stock's valuation. The failure shifts attention to the other, UX701, a treatment for Wilson disease. Data from that trial is expected in the second half of 2025.

The company's approved product, Crysvita, remains the near-term revenue driver. The drug earned $346 million last year, an 18% year-over-year increase in the latest quarter. Ultragenyx has been expanding Crysvita's label and geographic reach. That expansion does not replace the lost pipeline option from setrusumab.

Ultragenyx ended the latest quarter with $1.2 billion in cash and investments. That gives the company a multi-year runway without setrusumab revenue. The balance sheet means the failure does not force a near-term financing round. The stock price reaction reflected the loss of upside optionality, not a solvency risk.

The company has a history of pipeline volatility. A gene therapy trial for Angelman syndrome missed in 2022. The setrusumab result follows that pattern: a binary readout that resets expectations around a single asset. The broader thesis survives, narrowed to Crysvita and UX701.

For rare-disease investors, the next question is whether UX701 can deliver proof-of-concept data. Wilson disease is a smaller market than osteogenesis imperfecta. An approved drug there would diversify revenue beyond Crysvita. The company plans to present UX701 results at a medical meeting in the second half of 2025.

Until that data, Ultragenyx trades on Crysvita's execution and its cash position. The setrusumab failure removes a potential second growth driver. The stock's next catalyst is the UX701 readout, and the gap between now and that data point is where the market will weigh the risk.